guidance.fyi
Company, quarter, or anything said on a call

Q1 FY27 earnings callMax Healthcare Institute Limited

Max Healthcare posted strong revenue growth and continued its capacity expansion while embarking on a new medical education business.

Positive tone4 min readPublished the same day as the call

Numbers
MetricThis quarterChangeFive-quarter trend
Network Gross RevenueINR 2,982 crore16% YoY, 12% QoQ
Network Operating EBITDAINR 704 crore15% YoY, 3% QoQ
Network Operating EBITDA Margin24.8%
Profit After Tax (PAT)INR 357 crore
Average Revenue Per Occupied Bed (ARPOB)INR 81,9005% YoY, 5% QoQ
Network Average Occupancymore than 75%
International Patient RevenueINR 247 crore18% YoY
Digital RevenueINR 941 crore
Financials
From filed quarterly results. YoY and QoQ compare each metric on the same accounting basis.
QuarterRevenueNet profit (PAT)Basic EPS
Q3 FY25₹1,868.31 Cr+40% YoY+9.4% QoQ₹238.80 Cr-17.5% YoY-15.3% QoQ₹2.46-17.4% YoY-15.2% QoQ
Q2 FY25₹1,707.46 Cr+25.3% YoY+10.7% QoQ₹281.81 Cr+1.9% YoY+19.3% QoQ₹2.90+1.8% YoY+19.3% QoQ
Q1 FY25₹1,542.95 Cr+20.1% YoY+8.4% QoQ₹236.27 Cr-1.6% YoY-6.1% QoQ₹2.43-1.6% YoY-6.2% QoQ
Q4 FY24₹1,422.90 Cr+17.2% YoY+6.6% QoQ₹251.54 Cr+0.2% YoY-13.1% QoQ₹2.590% YoY-13.1% QoQ
Q3 FY24₹1,334.97 Cr+17% YoY-2.1% QoQ₹289.34 Cr+30.1% YoY+4.6% QoQ₹2.98+30.1% YoY+4.6% QoQ
TL;DR
  • Network revenue grew 16% YoY and 12% QoQ to INR 2,982 crore.
  • Operating EBITDA grew 15% YoY but margins were muted at 24.8% due to new capacity commissioning.
  • Occupancy remained above 75% despite a 13% increase in operational beds.
  • Acquired Kalinga Hospital in Bhubaneswar, targeting significant improvement in its 50% occupancy and INR 35,000 ARPOB.
  • Board approved new medical education business, expecting over 25% ROCE.
  • Multiple brownfield and greenfield expansion projects are on track for commissioning over the next few years.
Said on the call

“We are efficient providers of healthcare... I believe as far as efficiency is concerned; we are outliers.”

Abhay Soi
From the Q&A
TopicWhat management said
Parliamentary Committee ReportAbhay Soi believes the report focuses on affordability but the need for new beds and investment viability must be balanced; the company is not reassessing its expansion plans.
Kalinga Hospital TurnaroundManagement sees a 50-80% headroom for growth from the current 50% occupancy and INR 35,000 ARPOB, targeting a turnaround over the next 12 months through renovation and clinical program upgrades.
Max Smart & Nanavati Ramp-upCommissioned beds at Max Smart are at 80% occupancy; profitability ramp-up follows a standard trajectory of first occupancy, then revenue, then EBITDA, expected over the next couple of quarters.
Insurance RenewalsOngoing negotiations with GIPSA and other insurers; a previously agreed 6% automatic price revision is due, and discussions are ongoing for inflation-linked increases.
Medical Education BusinessThe board has given in-principle approval; a 150-seat college requires ~INR 300 crore capex, expected to deliver >25% ROCE, and will be funded through internal accruals.
Oncology Business PressureOncology revenue was impacted by discontinuation of high-value chemo drugs for institutional patients; normalization is expected from Q3 FY27 onwards as the impact annualizes.
Institutional Revenue ShareManagement stated the share of institutional business is coming down as a result of concerted effort and this trend is expected to continue.
Free Cash Flow & DSOLower free cash flow conversion (56% vs typical 62-65%) was due to a INR 250 crore build-up in accounts receivable (DSO increased from 87 to 95 days), partly from CGHS portal issues, which is expected to normalize.
Guidance
  • Remaining 50% of 400-bed brownfield tower at Max Smart to be handed over in current quarter.
  • Remaining 50 beds at Nanavati Max to be operationalized in current quarter.
  • Phased commissioning of 500-bed Gurgaon Sector 56 facility expected by end of this year.
  • Kalinga Hospital (Bhubaneswar) turnaround targeted over next 12 months.
  • Oncology business to start normalizing from Q3 FY27.
  • Medical college commercial operations expected to start in the next few years.
Source
Also this week
  • Manipal Hospitals delivered strong growth in its first quarter as a public company, driven by patient demand, high-acuity specialty care, and the integration of Sahyadri Hospitals.

    MANIPALHOSPharmaceuticals & Healthcare3 min read
  • Ind-Swift Laboratories LimitedQ1 FY27Positive tone

    The company delivered strong financial performance driven by its transformation into a focused FDF manufacturer, with new CDMO partnerships commercialized and sharp margin expansion.

    INDSWFTLABPharmaceuticals & Healthcare4 min read
  • Zydus Lifesciences LimitedQ1 FY27Positive tone

    Zydus Lifesciences started FY27 with strong double-digit growth across all key businesses, driven by branded formulations in India, international markets, and strategic advancements in specialty and innovation.

    ZYDUSLIFEPharmaceuticals & Healthcare4 min read
  • Gufic Biosciences LimitedQ1 FY27Positive tone

    Gufic Biosciences delivered strong Q1 growth driven by improved margins from its new Indore plant, progress on complex injectable capabilities, and a strategic shift in its international business model.

    GUFICBIOPharmaceuticals & Healthcare4 min read
  • Dishman Carbogen Amcis LimitedQ1 FY27Positive tone

    Despite a soft revenue quarter, management is focused on sales force expansion, tech transfers to India, and a significant debt refinancing to improve margins, projecting an optimistic future.

    DCALPharmaceuticals & Healthcare3 min read